Merck has completed the acquisition of NovaCardia, a privately-held, San Diego-based, clinical-stage pharmaceutical company focused on cardiovascular disease. The acquisition adds NovaCardia's investigational Phase III compound for acute heart failure, rolofylline, to Merck's drug line.

The Whitehouse Station, N.J.-based Merck acquired NovaCardia’s outstanding equity for $366.4 million.